2013年St Gallen乳腺癌会议国际专家共识荟萃

被引：120

作者：

王新昭 ^{[1
,2
]}

左文述 ^{[1
]}

刘琪 ^{[1
,2
]}

于志勇 ^{[1
]}

机构：

[1] 山东省肿瘤医院外科二病区山东省乳腺病防治中心

[2] 济南大学·山东省医学科学院医学与生命科学学院

来源：

中华肿瘤防治杂志 | 2013年 / 20卷 / 23期

关键词：

D O I：

10.16073/j.cnki.cjcpt.2013.23.006

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

<正>自2011年St Gallen会议共识以来,早期浸润性乳腺癌的治疗在各方面均有较大进展[1]。通过乳腺癌基因组分析发现,乳腺癌是一种异质性疾病,因此基因组研究将来可能影响乳腺癌的治疗决策[2-4]。最新研究显示,前哨淋巴结活检(sentinel lymph node biopsy,SLNB)能够代替腋窝淋巴结清除(axillary lymph node dissection,ALND)而不会影响患者的生存率,并

引用

页码：1859 / 1864

页数：6

共 19 条

[1]

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials [J].

Haviland, Joanne S. ;

Owen, J. Roger ;

Dewar, John A. ;

Agrawal, Rajiv K. ;

Barrett, Jane ;

Barrett-Lee, Peter J. ;

Dobbs, H. Jane ;

Hopwood, Penelope ;

Lawton, Pat A. ;

Magee, Brian J. ;

Mills, Judith ;

Simmons, Sandra ;

Sydenham, Mark A. ;

Venables, Karen ;

Bliss, Judith M. ;

Yarnold, John R. .

LANCET ONCOLOGY, 2013, 14 (11) :1086-1094

[2]

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study [J].

Drukker, C. A. ;

Bueno-de-Mesquita, J. M. ;

Retel, V. P. ;

van Harten, W. H. ;

van Tinteren, H. ;

Wesseling, J. ;

Roumen, R. M. H. ;

Knauer, M. ;

van 't Veer, L. J. ;

Sonke, G. S. ;

Rutgers, E. J. T. ;

van de Vijver, M. J. ;

Linn, S. C. .

INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (04) :929-936

[3]

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial [J].

Pivot, Xavier ;

Romieu, Gilles ;

Debled, Marc ;

Pierga, Jean-Yves ;

Kerbrat, Pierre ;

Bachelot, Thomas ;

Lortholary, Alain ;

Espie, Marc ;

Fumoleau, Pierre ;

Serin, Daniel ;

Jacquin, Jean-Philippe ;

Jouannaud, Christelle ;

Rios, Maria ;

Abadie-Lacourtoisie, Sophie ;

Tubiana-Mathieu, Nicole ;

Cany, Laurent ;

Catala, Stephanie ;

Khayat, David ;

Pauporte, Iris ;

Kramar, Andrew .

LANCET ONCOLOGY, 2013, 14 (08) :741-748

[4]

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label; randomised controlled trial.[J].Aron Goldhirsch;Richard D Gelber;Martine J Piccart-Gebhart;Evandro de Azambuja;Marion Procter;Thomas M Suter;Christian Jackisch;David Cameron;Harald A Weber;Dominik Heinzmann;Lissandra Dal Lago;Eleanor McFadden;Mitch Dowsett;Michael Untch;Luca Gianni;Richard Bell;Claus-Henning K?hne;Anita Vindevoghel;Michael Andersson;A Murray Brunt;Douglas Otero-Reyes;Santai Song;

[5]

Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer 15-Year Results of a Randomized Controlled Trial [J].

Martelli, Gabriele ;

Boracchi, Patrizia ;

Ardoino, Ilaria ;

Lozza, Laura ;

Bohm, Silvia ;

Vetrella, Gaetano ;

Agresti, Roberto .

ANNALS OF SURGERY, 2012, 256 (06) :920-924

[6]

Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases [J].

Xie, Jipan ;

Diener, Melissa ;

Sorg, Rachael ;

Wu, Eric Q. ;

Namjoshi, Madhav .

CLINICAL BREAST CANCER, 2012, 12 (04) :247-258

[7]

Adipose tissue cells, lipotransfer and cancer: A challenge for scientists, oncologists and surgeons [J].

Bertolini, Francesco ;

Lohsiriwat, Visnu ;

Petit, Jean-Yves ;

Kolonin, Mikhail G. .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2012, 1826 (01) :209-214

[8]

Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer [J].

Hassett, Michael J. ;

Silver, Samuel M. ;

Hughes, Melissa E. ;

Blayney, Douglas W. ;

Edge, Stephen B. ;

Herman, James G. ;

Hudis, Clifford A. ;

Marcom, P. Kelly ;

Pettinga, Jane E. ;

Share, David ;

Theriault, Richard ;

Wong, Yu-Ning ;

Vandergrift, Jonathan L. ;

Niland, Joyce C. ;

Weeks, Jane C. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) :2218-2226

[9]

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer [J].

Jackson, James G. ;

Pant, Vinod ;

Li, Qin ;

Chang, Leslie L. ;

Quintas-Cardama, Alfonso ;

Garza, Daniel ;

Tavana, Omid ;

Yang, Peirong ;

Manshouri, Taghi ;

Li, Yi ;

El-Naggar, Adel K. ;

Lozano, Guillermina .

CANCER CELL, 2012, 21 (06) :793-806

[10]

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS; a randomised trial.[J].Christina Davies;Hongchao Pan;Jon Godwin;Richard Gray;Rodrigo Arriagada;Vinod Raina;Mirta Abraham;Victor Hugo Medeiros Alencar;Atef Badran;Xavier Bonfill;Joan Bradbury;Michael Clarke;Rory Collins;Susan R Davis;Antonella Delmestri;John F Forbes;Peiman Haddad;Ming-Feng Hou;Moshe Inbar;Hussein Khaled;Joanna Kielanowska;

← 1 2 →